McKesson Corporation (MCK) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Total Cash From Operating Activities Chart for McKesson Corporation
McKesson Corporation (MCK) operating cash flow for FY2026 was USD 6.2B, a 1.2% change from FY2025. McKesson Corporation's operating cash flow grew from USD 195.1M in 1995 to USD 6.2B in 2026 (3054.8% over 31 years). Operating cash flow compound annual growth rate: 5-year CAGR of 6.3%, 10-year CAGR of 5.3%, 20-year CAGR of 4.1%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $101.59B
- Implied Share Price
- $871.38
- Enterprise Value
- $101.86B
- Revenue (TTM)
- $403.43B
- EBITDA
- $6.88B
- Profit Margin
- 1.18%
- Trailing P/E
- 22.83
- Forward P/E
- 18.76
- Price/Book (MRQ)
- 4.92
- Price/Sales (TTM)
- 0.25
- EV/EBITDA
- 14.19
- EV/Revenue
- 0.25
- Dividend Yield
- 0.00%
- Book Value
- $-18.10
- Free Cash Flow (FY2026)
- $5.72B
- Free Cash Flow Yield
- 5.63%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.